Retatrutide doubles semaglutide's weight loss, calorie restriction fails a mutation test and 41,047 dogs map a longer life, and one other thing worth your time this week.

Week of November 2nd, 2026

This week is about what actually moves the needle on aging and what only looks like it does. A phase 3 topline shows retatrutide more than doubling semaglutide's weight loss in type 2 diabetes. A Cell paper puts calorie restriction and the mutation theory of aging to the test. A huge dog cohort maps what predicts a longer life, and a centenarian study asks whether a common antibody problem stops climbing in the oldest old. One of the four is our favorite this week. Four findings, graded honestly. Here is what is worth your attention.

1. Retatrutide Doubles Semaglutide's Weight Loss in an 80-Week Head-to-Head Trial

Most people with type 2 diabetes need glucose control and weight loss from the same drug, and the current best option has a ceiling. Eli Lilly reported topline phase 3 results on October 28 from TRANSCEND-T2D-2, an 80-week open-label trial in 1,298 adults on metformin. Retatrutide 12 mg cut body weight 20.9% versus 9.4% for semaglutide 2 mg, and A1C fell 2.2 points versus 1.8.

Grade it as a strong signal that is not yet a paper. This is a company press release, not peer-reviewed data, and the trial was open-label. Discontinuation for side effects ran 7.9% on the 12 mg dose versus 2.7% on semaglutide, and dysesthesia was more common. Retatrutide is not approved anywhere. Wait for the full publication before weighing benefit against tolerability.

Eli Lilly and Company. Topline results from TRANSCEND-T2D-2, retatrutide versus semaglutide 2 mg (press release). October 28, 2026. ClinicalTrials.gov: NCT06260722 <https://investor.lilly.com/node/55186>

2. Calorie Restriction Cuts Mutations but Does Not Explain Longer Life

Fewer DNA mutations has long been a leading explanation for why eating less extends life. A Cell paper from Grońska-Pęski and colleagues, previewed in the same issue by Björn Schumacher of the University of Cologne, tested that idea directly. Calorie restriction did slow the accumulation of mutations, but the drop did not scale with how much lifespan was extended.

Grade it as an important mechanistic correction with no clinical use yet. The evidence is laboratory research on mutation rates, not a human trial, and the journal's commentary gives no effect sizes, so the numbers live in the full paper. The takeaway is that lowering mutation load is not the main way calorie restriction works, which points researchers to other mechanisms. This is Travis's favorite of the four, and here is why: it shows a popular aging theory failing a clean test, which is how the field gets sharper.

Schumacher B. Calorie restriction uncouples mutation rate from lifespan. Cell. 2026. DOI: 10.1016/j.cell.2026.09.038 <https://pubmed.ncbi.nlm.nih.gov/42956715/>

3. A 41,047-Dog Study Maps What Predicts a Longer Life

Dogs share our homes, our food and many of our age-related diseases, with lifespans compressed to about a decade, which makes them a fast model for human aging. The Dog Aging Project, with Weihsueh Chiu of Texas A&M and colleagues, followed 41,047 dogs through 2024 and reported in GeroScience. Median lifespan ranged from 14 years in small dogs to under 10 in giant purebreds, and 72 of 804 survey variables tracked with mortality.

Grade it as a solid observational map and nothing more. It is owner-reported survey data, so it shows association, not cause. Still, state-level dog mortality tracked human mortality (r = 0.43), which hints at shared environmental drivers. Health status, activity, behavior, environment and diet dominated the hits. The takeaway is a list of hypotheses for causal studies, not advice for your dog's bowl.

Chiu WA, Dunbar MD, Han G, et al. Factors associated with longevity in companion dogs: initial findings from the Dog Aging Project. GeroScience. 2026. DOI: 10.1007/s11357-026-02448-9 <https://pubmed.ncbi.nlm.nih.gov/42945030/>

4. Among Centenarians, an Antiviral-Blocking Antibody Stops Climbing

Autoantibodies that block type I interferons, a key antiviral signal, are rare before 65 and exceed 6% after 80. A multinational team led by Nanna Mørk at Aarhus University tested 938 centenarians from Denmark, Colombia, Australia and Japan and reported in the Journal of Human Immunity. In all, 51 people (5.4%) carried the antibodies, ranging from 3.3% in Japan to 9.1% in Colombia.

Grade it as a useful cross-sectional observation with a thin causal story. Prevalence leveling off after 80 fits the idea that these antibodies do not help people reach extreme old age, but a single snapshot cannot show who was lost along the way. It is a descriptive study, not a screening recommendation. Watch for follow-up on whether testing predicts severe viral infection.

Mørk N, Jensen JA, Bastard P, et al. The rise in prevalence of autoantibodies neutralizing type I interferons reaches a plateau in centenarians. Journal of Human Immunity. 2026. DOI: 10.70962/jhi.20260143 <https://pubmed.ncbi.nlm.nih.gov/42944855/>

Have a great week,

Travis and Winston

Medical disclaimer

The content above is for informational and educational purposes only and does not constitute medical, nutritional, or professional advice. It is not intended to diagnose, treat, cure, or prevent any disease and is not a substitute for personalized guidance from a licensed physician or other qualified healthcare provider. Individual needs and risks vary. Do not begin, stop, or modify any exercise regimen, dietary plan, medication (including retatrutide, semaglutide or other GLP-1 receptor agonists, or metformin), or supplement based on this article alone. Consult your doctor first, particularly if you have or suspect a cardiovascular, metabolic, kidney, gastrointestinal, or neurological condition, take prescription medications, or are pregnant or breastfeeding. Studies summarized here vary in design and quality; preclinical and animal findings often do not translate to humans, and associations reported in observational research do not prove cause and effect.